As per MRFR analysis, the Japan Infertility Market Size was estimated at 90.41 (USD Million) in 2024The Japan Infertility Market Industry is expected to grow from 102.0(USD Million) in 2025 to 360.0 (USD Million) by 2035. The Japan Infertility Market CAGR (growth rate) is expected to be around 12.148% during the forecast period (2025 - 2035).
Key Japan Infertility Market Trends Highlighted
In Japan, the infertility market is witnessing significant trends shaped by societal and economic factors. One key market driver is the increasing awareness and acceptance of assisted reproduction technologies. As public knowledge grows, couples experiencing infertility are more inclined to seek medical help, leading to higher demand for treatments such as in vitro fertilization (IVF) and artificial insemination. The Japanese government has recognized this challenge, implementing policies to provide financial support for fertility treatments, which further boosts participation rates in these programs. Opportunities in the Japan infertility market are expanding due to technological advancements in reproductive health.
Developments in genetic testing and embryo selection are improving success rates in fertility treatments, making them more attractive to prospective parents. Additionally, there is an increasing trend toward men seeking fertility assessments; as discussions about male infertility become more prominent, service providers are likely to develop more tailored solutions to attract male patients.
Recent times have seen a rise in the number of fertility clinics across Japan, fueled by the fertility tourism trend where couples from other countries seek treatments deemed more accessible in Japan due to its advanced medical facilities. Moreover, lifestyle changes and delayed marriages have contributed to a growing demographic seeking infertility solutions.Japanese society is gradually shifting towards a more supportive environment for couples facing infertility, translating into a more robust market filled with both challenges and opportunities. As such, the evolution of cultural perspectives towards infertility continues to shape the landscape, driving growth and innovation in the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Japan Infertility Market Drivers
Increasing Awareness and Demand for Fertility Treatments
In Japan, there has been a significant rise in the awareness surrounding infertility treatments, primarily due to initiatives led by health organizations and government entities that aim to educate the public about reproductive health. This increased awareness is promoting a higher demand for fertility treatments in the Japan Infertility Market Industry as couples seek assistance with family planning at later stages in life. According to the Ministry of Health, Labour and Welfare (MHLW), the number of couples receiving assisted reproductive technology (ART) services has increased drastically, with reported ART cycles rising from approximately 300,000 in 2005 to over 700,000 in recent years.
This trend showcases the growing acceptance of infertility treatment options, thereby contributing to the market's expansion. Furthermore, the Japanese Society of Obstetrics and Gynecology has been actively promoting fertility awareness campaigns, further fueling the demand within the market. The proactive stance taken by these organizations is instrumental in driving the growth of the Japan Infertility Market.
Government Initiatives and Funding for Fertility Treatments
The Japanese government’s commitment to addressing the country’s declining birth rate is resulting in increased funding and favorable policies for fertility treatments, positively impacting the Japan Infertility Market Industry. In recent years, government measures, such as subsidies for ART treatments, have been implemented to support couples facing infertility challenges. The MHLW has allocated significant budgets for these programs, which has led to more affordable treatment options for citizens.For instance, it was reported that government subsidies for fertility treatments have led to a 50% reduction in out-of-pocket expenses for ART procedures for eligible couples. Such initiatives indicate the government’s dedication to combating declining birth rates through support for reproductive health, thus serving as a strong driver for market growth.
Technological Advancements in Fertility Treatments
The Japan Infertility Market is experiencing substantial growth due to rapid technological advancements in fertility treatments. Over the past decade, innovations in reproductive technologies, including preimplantation genetic testing (PGT) and improved embryo culture systems, have enhanced the success rates of ART procedures. According to the Japan Society of Fertility and Sterility, these modern techniques have increased the success rate of in vitro fertilization (IVF) cycles, showing a rise from approximately 30% to over 40% for women under 35 years of age.As fertility clinics in Japan adopt these state-of-the-art technologies, couples are more likely to pursue treatment options, thus driving demand within the Japan Infertility Market Industry. The continuous evolution of technologies also allows clinics to cater to a broader demographic, further amplifying the market potential.
Japan Infertility Market Segment Insights:
Infertility Market Sex Insights
The Japan Infertility Market has been increasingly focusing on the Sex segment, which encompasses a variety of dynamics influencing fertility challenges among individuals. This market segment's significance stems from the fact that infertility affects a considerable percentage of couples in Japan, where societal and demographic shifts have impacted reproductive health. The growing awareness and increasing acceptance of fertility treatments, along with advancements in reproductive technologies, have contributed to a robust market environment. In Japan, increasing rates of infertility due to various lifestyle factors and the rising age of childbearing present substantial challenges that drive the demand for related services.
Within this context, the needs of males and females differ, with distinct yet interrelated causes of infertility. Male infertility, encompassing issues such as low sperm count and motility, often receives less attention but is a critical factor in half of the infertility cases. Female infertility is commonly associated with conditions such as polycystic ovary syndrome (PCOS), endometriosis, and age-related factors, all of which are relevant in a rapidly aging society like Japan. Moreover, couples sometimes experience unexplained infertility, which can be particularly distressing as it lacks a clear medical explanation, further amplifying the emotional burden associated with fertility challenges.
As Japanese society continues to evolve, increased collaboration between healthcare providers and potential patients is vital to demystifying infertility and encouraging open discussions. The government has also been actively promoting reproductive health initiatives, aiming to address declining birth rates and provide support systems for couples facing infertility. All these factors are contributing to a vibrant landscape within the Japan Infertility Market, as stakeholders actively work to meet the emerging needs across communities.
The Japan Infertility Market is characterized by a growing emphasis on personalized treatment options and innovative solutions tailored to both male and female reproductive health issues. Collaborations among healthcare professionals, researchers, and technology developers highlight the commitment to advancing understanding and treatment efficacy in this area. This interactivity fosters an environment rich in opportunities for growth and innovation, effectively addressing the complexities of infertility challenges faced by individuals in Japan. In summary, the dynamics within the Sex segment of the Japan Infertility Market reflect a multi-faceted approach that targets both the physical and emotional aspects of infertility, with the aim of providing comprehensive support for those on this journey.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Infertility Market Diagnosis Insights
The Diagnosis segment of the Japan Infertility Market plays a vital role in addressing reproductive health concerns across various demographics. This segment encompasses Men Diagnostic Tests, Women Diagnostic Tests, and General Diagnostic Tests, reflecting the comprehensive approach to understanding infertility issues in Japan. Men Diagnostic Tests are essential given rising male infertility rates, which are influenced by lifestyle factors and environmental aspects prevalent in urbanized areas. Women Diagnostic Tests attract considerable attention, as they are pivotal in identifying hormonal imbalances and structural abnormalities that can hinder fertility, thus making them a significant focal point in reproductive medicine.
General Diagnostic Tests serve as the foundational screening tools that assist clinicians in forming an initial understanding of a patient’s health, enabling timely intervention. The Japanese government has acknowledged the increasing need for effective infertility solutions, paving the way for advancements and innovations in diagnostic technology. As a result, the Japan Infertility Market is experiencing trends driven by technological advancements, patient education, and healthcare policy improvements. Challenges such as societal stigma surrounding infertility and the high costs associated with advanced diagnostic testing present opportunities for market growth, positioning the Diagnosis segment as a cornerstone in the journey toward successful conception.
Infertility Market Drugs Insights
The Japan Infertility Market, particularly in the drugs segment, plays a crucial role in addressing reproductive challenges faced by couples. Clomiphene Citrate has been a well-regarded choice due to its effectiveness in stimulating ovulation, often being one of the first-line treatments for female infertility. Letrozole is gaining traction as an alternative to Clomiphene Citrate, especially among those with polycystic ovary syndrome (PCOS), showcasing its growing acceptance within the medical community. Serophene is recognized for its role in providing fertility solutions, reflecting the diverse treatment options available.
Hormone treatments are significant, as they help balance hormonal levels, which is essential for enhancing fertility outcomes. Other treatment modalities have emerged as complementary solutions, catering to specific needs of patients, thus enriching the Japan Infertility Market segmentation. Together, these drugs promote advancements in reproductive health and contribute towards enhanced fertility strategies, making the segment vital for a growing population in Japan seeking family planning solutions. As Japan faces a declining birth rate, these drug options exemplify advancements in reproductive medicine, ultimately benefiting couples striving to conceive.
Infertility Market Technology Insights
The Japan Infertility Market is significantly shaped by its Technology segment, which includes advanced medical procedures and techniques for addressing infertility issues. Among these, Assisted Reproductive Technology (ART) is crucial commonly associated with in vitro fertilization (IVF), and it represents a growing trend due to its effectiveness and increasing acceptance among couples facing fertility challenges. Intrauterine Insemination (IUI) also plays a vital role, particularly as a less invasive option, making it increasingly popular for those seeking timely solutions.
Additionally, surgical interventions remain a key component of the technology landscape, often aimed at resolving anatomical issues that may hinder fertility. The growing awareness and acceptance of these technologies in Japan, influenced by supportive government initiatives and increasing investment in healthcare infrastructure, are pivotal in driving growth. Enhanced access to these technologies, coupled with a societal shift towards addressing fertility issues, underscores their importance in the overall landscape of the Japan Infertility Market, addressing both immediate and long-term reproductive health needs.Moreover, challenges such as rising costs and regulatory considerations continue to affect market dynamics, offering opportunities for innovation and improved patient care.
Japan Infertility Market Key Players and Competitive Insights
The Japan Infertility Market is characterized by a complex landscape that involves various stakeholders, including medical institutions, private clinics, research organizations, and technology providers. This market has seen significant growth due to increasing awareness about infertility issues, coupled with advancements in reproductive technologies and growing demand for assisted reproductive services. The competitive dynamics within this market are driven by innovation, regulatory considerations, and the availability of specialized treatment options that cater to diverse patient needs.
With the rise in infertility rates, there is a pressing requirement for effective solutions, which has led to increased investment in research and development of infertility treatments and technologies, creating a competitive environment where companies strive to offer cutting-edge services and products.EGlobal Trade and Technology Company has made a significant mark in the Japan Infertility Market through its robust technological solutions that support fertility treatments. With a strong focus on integrating advanced technologies such as artificial intelligence and data analytics, EGlobal Trade and Technology Company enhances the efficacy and efficiency of fertility interventions.
The company is recognized for its commitment to improving patient outcomes by offering innovative diagnostic tools and treatment protocols that are tailored to the needs of Japanese patients. Its strategic partnerships with healthcare providers and research institutions have further solidified its presence in the market, enabling the company to leverage its technological advantages to foster collaboration and drive innovation in infertility solutions within Japan.Tokyo University is a leading institution in the Japan Infertility Market, recognized for its groundbreaking research and contribution to reproductive medicine.
The university is instrumental in developing various key products and services, including advanced fertility treatments and comprehensive education programs for healthcare professionals. Tokyo University's strong reputation and extensive research facilities empower it to foster collaborations with private clinics and pharmaceutical companies, enhancing its market presence.
The university's strengths lie not only in its innovative research initiatives but also in its ability to attract funding and partnerships that facilitate advancements in infertility treatments. In terms of mergers and acquisitions, Tokyo University has successfully formed alliances with several private entities to expand their research capabilities and enhance the translation of research findings into practical applications for infertility treatments in Japan. This collaborative approach underscores its commitment to addressing infertility challenges through effective science-based solutions.
Key Companies in the Japan Infertility Market Include
Japan Infertility Market Industry Developments
The Japan Infertility Market has been witnessing significant developments recently, particularly from prominent entities such as Ferring Pharmaceuticals, Mitsubishi Tanabe Pharma, and IVF Japan. In June 2023, Ferring Pharmaceuticals announced advancements in their fertility treatment options, focusing on enhancing patient comfort and success rates. Concurrently, Mitsubishi Tanabe Pharma has been engaged in ongoing research and partnerships aimed at expanding their product portfolio in reproductive healthcare. Institutions such as Tokyo University and Rikkyo University have been collaborating on innovative studies related to infertility, aiming to improve treatment methodologies.
Recent mergers and acquisitions in this sector remain relatively sparse; however, notable advancements include joint ventures between universities like Juntendo University and AI Medical Service, focusing on integrating AI technologies in fertility treatments announced in August 2023. The market has seen substantial growth, driven by increasing awareness of infertility issues and the demand for assisted reproductive technologies, contributing to an estimated market valuation increase of approximately 15% over the last two years. Changes in societal attitudes towards infertility and government support have further propelled innovation in this rapidly evolving field in Japan.
Japan Infertility Market Segmentation Insights
Infertility MarketDiagnosisOutlook
Infertility MarketDrugsOutlook
Infertility MarketTechnologyOutlook
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 90.41(USD Million) |
| MARKET SIZE 2024 | 102.0(USD Million) |
| MARKET SIZE 2035 | 360.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.148% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | EGlobal Trade and Technology Company, Tokyo University, Ferring Pharmaceuticals, Mitsubishi Tanabe Pharma, Rikkyo University, ASAHI INTECC, Juntendo University, IVF Japan, Shinshu University, Tsukuba University, AI Medical Service, Medirom Healthcare Technologies, Tamagawa University, Kinki University, Monsanto |
| SEGMENTS COVERED | Sex, Diagnosis, Drugs, Technology |
| KEY MARKET OPPORTUNITIES | Rising age of first-time parents, Increasing awareness of infertility treatments, Advancements in reproductive technology, Growing demand for egg/sperm donation, Expanding telehealth services in fertility. |
| KEY MARKET DYNAMICS | rising infertility cases, advanced reproductive technologies, increasing healthcare expenditure, supportive government policies, growing awareness and education |
| COUNTRIES COVERED | Japan |
Frequently Asked Questions (FAQ) :
The Japan Infertility Market is expected to be valued at 102.0 million USD in 2024.
By 2035, the Japan Infertility Market is anticipated to reach a value of 360.0 million USD.
The Japan Infertility Market is expected to grow at a CAGR of 12.148% from 2025 to 2035.
In 2024, the female segment of the Japan Infertility Market is expected to be valued at 45.0 million USD, making it the largest.
The male segment of the Japan Infertility Market is projected to reach 126.0 million USD by 2035.
Major players in the Japan Infertility Market include EGlobal Trade and Technology Company, Ferring Pharmaceuticals, and IVF Japan.
The unexplained infertility segment is expected to be valued at 22.0 million USD in 2024.
The female infertility segment is expected to grow to 162.0 million USD by 2035.
The unexplained infertility segment is anticipated to reach 72.0 million USD in 2035.
Challenges such as high treatment costs and societal pressures are affecting the growth of the Japan Infertility Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
